- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| EMLA (Local anaesthesia) |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Methaemoglobinaemia is observed more frequently in neonates and infants, often due to overdosing.
Purpura, petechiae (especially after longer application times in children with atopic dermatitis or mollusca contagiosa)
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Premature infants and children aged under 12 months treated with drugs that may induce methaemoglobinaemia.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Lidcaine+prilocaine (Emla):
Due to the risk of increased methaemoglobin levels, do not use in preterm infants with a gestational age < 37 weeks or on the genitals of children younger than 12 years; sufficient efficacy in circumcision and heel prick has not been demonstrated. Due to its size, the patch is less suitable for certain body parts of children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Amides | ||
|---|---|---|
| N01BB08 | ||
| N01BB01 | ||
| N01BB10 | ||
| N01BB02 | ||
| N01BB52 | ||
| N01BB52 | ||
| N01BB03 | ||
| N01BB04 | ||
| N01BB09 | ||
| Esters of benzoic acid | ||
|---|---|---|
| N01BC01 | ||
| ESTERS OF BENZOIC ACID | ||
|---|---|---|
| N01BC01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Aspen Pharma Trading Limited, SmPC EMLA (RVG 11015/15721) 03-12-2021, www.geneesmiddeleninformatiebank.nl
- Eurocept International BV,, SmPC Rapydan (RVG 100315) 26-12-2011, www.geneesmiddeleninformatiebank.nl
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
